Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis - PubMed (original) (raw)
Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis
Guido Torzilli et al. Arch Surg. 2008 Nov.
Abstract
Hypothesis: Using an algorithm for selection of patients with hepatocellular carcinoma (HCC) for surgery, Barcelona Clinic Liver Cancer (BCLC) classification stage B and stage C disease is not a contraindication.
Design: Prospective cohort study.
Setting: University tertiary care hospital.
Patients: Among 163 consecutive patients with HCC, 120 (73.6%) underwent surgery; 113 of 120 (94.2%) underwent resection. Of 113 patients, 61 (54.0%) had BCLC stage 0 or A disease, 24 (21.2%) had stage B disease, and 28 (24.8%) had stage C disease.
Interventions: Surgical strategy was based on the relationship of the tumor to the intrahepatic vascular structures on intraoperative ultrasonography.
Main outcome measures: Mortality, morbidity, rate of cut edge local recurrences, and long-term outcome were evaluated. P < .05 was considered statistically significant.
Results: Hospital mortality was 0.9%. The overall morbidity was 27.4%, and major morbidity was 3.5%. After a median follow-up of 24 months (range, 1-65 months), there was no cut edge recurrence. For patients with BCLC stages 0 or A, B, and C disease, the 3-year overall survival rates were 81%, 67%, and 74%, respectively (P =.24); the 3-year disease-free survival rates were 30%, 35%, and 15%, respectively (P =.85); and the 3-year hepatic disease-free survival rates were 39%, 44%, and 17%, respectively (P =.79).
Conclusions: Patients with BCLC stage B and stage C HCC can tolerate hepatic resection with low mortality, acceptable morbidity, and survival benefits if resection is performed under strict intraoperative ultrasonographic guidance. These results should prompt revision of the BCLC recommendations.
Similar articles
- Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.
Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, Hasegawa S, Tsubouchi H; Kagoshima Liver Cancer Study Group. Ueno S, et al. J Hepatobiliary Pancreat Surg. 2009;16(3):359-66. doi: 10.1007/s00534-009-0069-7. Epub 2009 Mar 20. J Hepatobiliary Pancreat Surg. 2009. PMID: 19300896 - [Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature].
Neeff H, Makowiec F, Harder J, Gumpp V, Klock A, Thimme R, Drognitz O, Hopt UT. Neeff H, et al. Zentralbl Chir. 2009 Apr;134(2):127-35. doi: 10.1055/s-0028-1098881. Epub 2009 Apr 20. Zentralbl Chir. 2009. PMID: 19382043 Review. German. - Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment.
Vauthey JN, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, Lerut J, Chapman WC, Hemming AW, Neuhaus P. Vauthey JN, et al. J Am Coll Surg. 2007 May;204(5):1016-27; discussion 1027-8. doi: 10.1016/j.jamcollsurg.2006.12.043. J Am Coll Surg. 2007. PMID: 17481532 - Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver.
Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Chang CH, et al. Arch Surg. 2004 Mar;139(3):320-5; discussion 326. doi: 10.1001/archsurg.139.3.320. Arch Surg. 2004. PMID: 15006892 - Surgical management of hepatocellular carcinoma: is the jury still out?
Morris-Stiff G, Gomez D, de Liguori Carino N, Prasad KR. Morris-Stiff G, et al. Surg Oncol. 2009 Dec;18(4):298-321. doi: 10.1016/j.suronc.2008.08.003. Epub 2008 Dec 5. Surg Oncol. 2009. PMID: 19062271 Review.
Cited by
- Molecular refinement of clinical staging in hepatocellular carcinoma patients evaluated for potentially curative therapies.
Vitale A, Navaglia F, RamÃrez Morales R, Frigo AC, Basso D, D'Amico F, Zanus G, Bonsignore P, Farinati F, Burra P, Senzolo M, Grigoletto F, Plebani M, Cillo U. Vitale A, et al. PLoS One. 2011;6(9):e23093. doi: 10.1371/journal.pone.0023093. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21912636 Free PMC article. Clinical Trial. - Microvascular infiltration has limited clinical value for treatment and prognosis in hepatocellular carcinoma.
Portolani N, Baiocchi GL, Molfino S, Benetti A, Gheza F, Giulini SM. Portolani N, et al. World J Surg. 2014 Jul;38(7):1769-76. doi: 10.1007/s00268-013-2426-6. World J Surg. 2014. PMID: 24378549 - Controversies and evidence of hepatic resection for hepatocellular carcinoma.
Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Zhong JH, et al. BBA Clin. 2016 Oct 11;6:125-130. doi: 10.1016/j.bbacli.2016.10.001. eCollection 2016 Dec. BBA Clin. 2016. PMID: 27761414 Free PMC article. Review. - Surgical Resection plus Radiofrequency Ablation versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Zhou C, Zhang X, Peng Y, Zhou K, Hu J, Yu L, Chen F, Qiu S, Zhou J, Fan J, Zhang L, Wang Z. Zhou C, et al. J Cancer. 2019 Jun 24;10(17):3933-3940. doi: 10.7150/jca.29501. eCollection 2019. J Cancer. 2019. PMID: 31417637 Free PMC article. - Sorafenib and surgery for hepatocellular carcinoma - a controversial relation: Lesson learned?
Torzilli G. Torzilli G. Glob Health Med. 2023 Aug 31;5(4):246-248. doi: 10.35772/ghm.2023.01020. Glob Health Med. 2023. PMID: 37655183 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical